FLINT, MI- The Johnson and Johnson Jenssen vaccine is one of the three approved Covid-19 vaccines in the United States. Unlike the Pfizer and Moderna vaccines, J&J only requires one dose instead of two. The Johnson and Johnson Jenssen vaccine has a 66.3 percent effectiveness globally and 72 percent in the United states compared to the 94-95 percent effectiveness found in Pfizer and Moderna (CDC). However, according to the CDC, the vaccine had high efficacy at preventing hospitalizations and deaths in the clinical trials and no one who got Covid-19 at least 4 weeks after receiving the vaccine had to be hospitalized. People have the most protection after 2 weeks of receiving the dose. 

On Tuesday, April 13th, 2021, the CDC recommended that the J&J/Jenssen vaccine be put on a pause. According to the CDC, as of April 12th, 6.8 million doses of the vaccine were administered. Six cases of a rare and severe blood clot clot called cerebral venous sinus thrombosis were reported in the U.S. All cases occurred in women aged 18-48, and symptoms occurred 6-13 days after vaccination. The CDC has now resumed the use of the vaccine. The CDC states that the potential benefits of the vaccine outweighs the known potential risks. They also add that women younger than 50 years old should be aware of the risk and that there are other vaccine options in which this particular risk has not been seen.